Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies

Launched by UNIVERSITY HOSPITAL, LIMOGES · Nov 20, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of inhaled aromatherapy on managing nausea and vomiting caused by chemotherapy in patients with blood cancers, known as hematological malignancies. The researchers hope that using aromatherapy will help improve these symptoms, along with enhancing quality of life and appetite for those participating in the study.

To join this trial, participants must be over 18 years old, have a blood cancer, and be starting chemotherapy for the first time. They should be able to use an aromatherapy stick and must be comfortable reading, writing, and speaking French. It's important to note that individuals with certain conditions, like asthma or allergies to specific essential oils, will not be eligible. Participants can expect to use the aromatherapy as part of their treatment and will be monitored for any changes in their nausea and vomiting symptoms. This study represents a holistic approach to care, focusing on the well-being of cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged over 18 years,
• • Chemo-naive patients at inclusion,
• • Patients with haematological malignancies treated treated with chemotherapy,
• • Patients physically and mentally able to use the aromastick,
• • Patients who speak, read and write French,
• • Patients who have given signed consent,
• • Patients with social security cover.
• Exclusion Criteria:
• • Asthmatic patients.
• • Patients with anosmia.
• • Patients allergic to EO, lemon or ginger.
• • Patients who have already received aromatherapy to treat chemotherapy-induced nausea and vomiting,
• • Patients practising herbal medicine or acupuncture,
• • Pregnant and breast-feeding women,
• • Patients under guardianship, tutorship or curatorship,
• • Patients taking part in interventional studies involving antiemetic drugs or nutritional products,
• • Patients who have already had cancer.